Why the study?
Does sulphinpyrazone reduce human platelet aggregation ex vivo compared to naproxen?
Does sulphinpyrazone reduce human platelet aggregation ex vivo compared to naproxen?
The anti-aggregant activity of sulphinpyrazone is too weak to be the major factor in its reported effect on reducing cardiac death.
Sulphinpyrazone shows weak ex vivo anti-aggregant activity versus naproxen; leaves open alternative mechanisms for reported cardiac mortality reduction.
1 The effects of single doses of naproxen and sulphinpyrazone and of 4 and 8 days treatment with sulphinpyrazone on human platelet responsiveness were compared. 2 A single dose of sulphinpyrazone had no effect whereas a single dose of naproxen caused a five-fold depression in responsiveness to collagen. 3 Repeated administration of sulphinpyrazone led to a weak and equivocal inhibitory effect on collagen-induced aggregation, second phase aggregation in response to ADP and adhesion to collagen. There was no effect on ADP-induced first phase aggregation, adrenaline-induced second phase aggregation or platelet retention in glass bead columns. 4 It is concluded that the anti-aggregant activity of sulphinpyrazone is too weak to be a major factor in its reported effect on the incidence of cardiac death.
No takes yet. Share an insight, caveat, or question.
Nunn et al. (1980) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: